Evaluating SLC3A2 expression from the ZCC precision medicine platform, we also found significantly higher expression in the cohort of DMGs compared to other high-risk pediatric cancers including relapsed/refractory high-risk neuroblastoma (Fig. 2b, c, Supplementary Table 4). The gene discussed is SLC3A2; the disease is cancer.